Business Wire

EIT-URBAN-MOBILITY

17.11.2022 15:39:38 CET | Business Wire | Press release

Share
Tomorrow.Mobility Shines Light on the New Driving Forces for More Liveable and Sustainable Cities

(15-17 November 2022) – Tomorrow.Mobility World Congress (TMWC) is a global event, co-organised by Fira de Barcelona and EIT Urban Mobility, in the Gran Via venue of Fira de Barcelona, focused on promoting the design and adoption of new sustainable urban mobility models and jointly organised with the Smart City Expo World Congress.

Over 80 speakers such as Kelly Larson, director of the Road Safety Programme at Bloomberg Philanthropies; Karen Vancluysen, secretary general of POLIS; Marco te Brömmelstroet, professor of Future of Urban Mobility at the University of Amsterdam; Mikael Colville-Andersen, Urban Design Expert and Maria Tsavachidis, CEO of EIT Urban Mobility, participated in the more than 20 congress and talks in Tomorrow.Mobility. EIT urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, sponsored the venue of more than 20 innovative startups. At this edition, two studies produced by EIT Urban Mobility are unveiled. FULL STUDY & Press Summary in the google drive.

The 15-minute city

The 15-minute city, is a recent concept that has taken momentum in wake of the pandemic and has been picked up by many European cities. The goal is to create a city where people could reach all their basic essential social functions like living, working, commerce, healthcare, education, and entertainment at a 15-minute by walk. In Europe, more than €1bn in cycling-related infrastructure and 2,300 kilometers of new bike lanes have been spent since the pandemic began.

Three workshops were conducted with planning practitioners from the metropolitan region of Amsterdam, Ghent, Madrid, Milan, and Munich. A key output of this study is a roadmap for the implementation of ±15-minute city strategies to ensure access all citizen’s needs, and in connection with suburb areas. 15-Minute City concepts need to be adapted to local circumstances and population groups: older people walking speed is on average around 3.5 km/h while the average speed is considered 5km/h. Hence, a 15-minute walk could represent 900-1000m at an average speed, while at a reduced speed it could be 700m.

Urban Air Mobility

Given the fast pace of innovation, air mobility is expected to become a reality in Europe within 3-5 years and air space above cities could become an extension of public space on the ground. The European UAM market size is predicted to be 4.2 billion EUR by 2030, representing a 31% global share1. To set up the scenes for an inclusive urban air mobility scheme, this first study explores the different evolution perspectives of the sector. The study collected practitioners’ insights on the development and implementation of UAM from 12 European countries from the academic, public, and private sector.

Out of the sectorial experts, 89% expect that UAM applications will play a very important or important role in improving medical transport and support in medical emergency services. 63% of questionnaire respondents think that in the logistics field, UAM will play an important or a very important role in the transport of packages in industrial spaces. By contrast, only a minority of experts see a significant role in UAM applications in e-commerce and food deliveries. In terms of challenge, when moving forward with UAM, it is essential to consult citizens and it´s important for them to feel safe, where subjective safety matters as much as objective ones. Traffic noise is the second main concern raised by the study, after safety, for the development of Urban Air Mobility for European citizens.

About EIT Urban Mobility

EIT Urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, aims to accelerate solutions and the transition towards a user-centric, integrated and truly multimodal transport system. As the leading European innovation community for urban mobility, EIT Urban Mobility works to avoid fragmentation by facilitating collaboration between cities, industry, academia, research and innovation.

1 https://www.easa.europa.eu/en/newsroom-and-events/press-releases/easa-publishes-results-first-eu-study-citizens-acceptance-urban#group-easa-downloads

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005677/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye